Curiumthe pharmaceutical company specialized in nuclear medicine, a novel formula in cancer treatment, has acquired the Institute of Applied Radiopharmacy of Barcelona (IRAB). The operation has been communicated to the National Securities Market Commission, which will now have to decide whether the purchase does not affect competition.
With the acquisition, Curium enters Catalonia, one of the few regions in which it was not yet physically present. It currently has 27 centers in Spain, of which four are in Madrid and eleven in Andalusia. The Institute of Applied Radiopharmacy of Barcelona is dedicated to the development, production and marketing of PET (positron emission tomography) radiopharmaceuticals in one of the most cutting-edge biomedical research environments in Europe, providing service excellence and needs-oriented product reliability. existing and future of the public and private clinical sector.
In Spain, in addition to Curium, the other company that is dedicated to nuclear medicine is Novartiswho has three centers in the national territory, including one in Castilla y León that is currently being built. In fact, both companies are old acquaintances.
In February 2021, the National Markets and Competition Commission fined both companies 5.76 million for forming a cartel in the supply of the radiopharmaceutical fluorodeoxyglucose (18-FDG). The CNMC then said that the two firms adopted a joint strategy to distribute contracts for the supply of radiopharmaceuticals to public and private hospitals.
#Curium #consolidates #Spain #purchase #IRAB
